Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients

Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we r...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 13; p. 794512
Main Authors Papadopoulos, Sotirios, Koulouris, Pantelis, Royer-Chardon, Claire, Tsoumakidou, Georgia, Dolcan, Ana, Cherix, Stephane, Matter, Maurice, Omoumi, Patrick, Digklia, Antonia
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 23.03.2022
Subjects
case report
desmoid tumors
Drug-Related Side Effects and Adverse Reactions
Endocrinology
Fibromatosis, Aggressive - drug therapy
Fibromatosis, Aggressive - pathology
Humans
Imatinib Mesylate - adverse effects
lymphadenopathy
Lymphadenopathy - chemically induced
pazopanib
Protein Kinase Inhibitors - adverse effects
side effects
tyrosine kinase inhibitor
case report
side effects
desmoid tumors
tyrosine kinase inhibitor
lymphadenopathy
pazopanib
Online AccessGet full text

Cover

More Information
Summary:Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we report two cases of patients with desmoid tumors, treated with pazopanib and imatinib, who developed reactional lymphadenopathy. As this side effect is presented as a newly formed mass, it can result in new diagnostic questions and added imaging tests and can even lead to discontinuation of the treatment. This report may help the clinicians facing similar problems adopt a "watch and wait" approach.
Bibliography:Reviewed by: Hiroshi Ureshino, Saga University, Japan; Marco Santoro, Università degli Studi di Palermo, Italy
This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology
Edited by: Wen Zhou, Case Western Reserve University, United States
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2022.794512